Annora Pharma
Annora Pharma is the formulations subsidiary of Hetero Group, manufacturing generic tablets, capsules, pellets, liquid orals, suppositories and dry powder syrups at a USFDA- and EU-compliant facility near Hyderabad, India, and exporting to the US, EU, GCC, LATAM, ASEAN and China.
- Company typePrivate
- Founded2016
- HeadquartersSangareddi, India
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Annora Pharma does
Annora Pharma Private Limited is the formulations subsidiary of Hetero Group, established in 2016 and headquartered at a 35-acre cGMP-compliant manufacturing facility near Hyderabad in Sangareddy District, Telangana, India. The company manufactures a portfolio of generic pharmaceutical products in multiple dosage forms — tablets, capsules, pellets, liquid orals, suppositories and dry powder syrups — and serves global regulated markets including the United States, the European Union, the Gulf Cooperation Council, Latin America and ASEAN, with recent entry into China via hospital tenders for products such as Dapagliflozin.
The technical platform is built around Schedule M, USFDA and EU-good-manufacturing-practice-compliant production lines and was extended in 2025–2026 through a partnership with AltiusHub to deploy an AI-native serialization, track-and-trace and regulatory compliance platform across export operations, targeting up to 45% improvement in serialization efficiency and 100% real-time visibility of serialized drug products within three months. The facility and process know-how — including multi-dosage-form capability and accumulated ANDA pipeline execution — constitute the core operating technology, with AI layered on top as a compliance and supply-chain visibility layer rather than a core scientific differentiator.
Commercially, Annora operates a B2B export model selling generic formulations to enterprise buyers, government hospital systems and regulated-market distributors across more than five global regions, leveraging Hetero Group's regional distribution channels. Revenue mechanics are anchored in volume-based generic-drug supply contracts (one-time license / supply arrangements) rather than disclosed subscription or recurring-revenue pricing; no pricing, revenue figures or independent funding rounds are publicly disclosed, and the company has no app or consumer-facing software product. Strategic direction and capacity allocation sit with the Hetero Group parent, with Annora's role focused on formulations manufacturing and global export execution.
Annora Pharma firmographics
Firmographics- Name
- Annora Pharma
- Legal name
- Annora Pharma Pvt. Ltd.
- Website
- https://annorapharma.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Annora Pharma is the formulations subsidiary of Hetero Group, manufacturing generic tablets, capsules, pellets, liquid orals, suppositories and dry powder syrups at a USFDA- and EU-compliant facility near Hyderabad, India, and exporting to the US, EU, GCC, LATAM, ASEAN and China.
- Ownership category
- akta.pro rank
Annora Pharma industry classification
Industry- Product category
- Generic Pharmaceuticals Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)
- akta.pro secondary industry
- Oral Solid Dose (OSD) Generics (HLAIABAD)
Keywords
Where Annora Pharma is headquartered
LocationHeadquarters
- HQ city
- Sangareddi
- HQ country
- India
- HQ region
- Asia
Offices1 record
Markets served
Annora Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- Generic Pharmaceutical Manufacturing and Export: Annora Pharma operates as the formulations subsidiary of Hetero Group, manufacturing generic pharmaceutical products for global export across regulated markets including US, EU, GCC, LATAM, and ASEAN regions
Distribution channels1 record
Annora Pharma product offering
Product offeringCore offering
Annora Pharma manufactures generic pharmaceutical formulations including tablets, capsules, pellets, liquid orals, suppositories, and dry powder syrups at a 35-acre cGMP-compliant facility near Hyderabad, India. The company exports these generic medicines to regulated markets across the US, EU, GCC, LATAM, ASEAN, and China, with operations meeting Schedule M, USFDA, and European Regulatory Agency guidelines. It operates as the formulations subsidiary of Hetero Group and supports multi-jurisdictional serialization and regulatory compliance through an AI-based traceability platform.
Product overview
Annora Pharma is a formulations-focused pharmaceutical company that manufactures a diverse portfolio of generic medications. The company operates as a manufacturing organization producing tablets, capsules, pellets, liquid orals, suppositories, and dry powder syrups across multiple therapeutic areas. The primary product identified is Dapagliflozin for diabetes treatment. The company operates as the formulations subsidiary of Hetero Group, serving global regulated markets including the US, EU, GCC, LATAM, and ASEAN regions through its cGMP-compliant manufacturing facility near Hyderabad, India.
Differentiator
Problem solved
Functional benefit
Products and services
- Dapagliflozin
Quantifiable outcome
- 45% improvement in serialization efficiency
- +1 more outcomes
Companies that use Annora Pharma
Customer profileNamed customers2 records
Segments1 record
Ideal customer profiles1 record
Annora Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Annora Pharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- AltiusHubcoreAnnora Pharma expanded its collaboration with AltiusHub to deploy an AI-native serialization, track & trace, and regulatory compliance platform across its export operations. The deployment is expected to improve serialization efficiency by up to 45% and enable real-time visibility across 100% of serialized drug products within three months, replacing fragmented legacy systems with a unified platform supporting compliance across US, EU, GCC, LATAM, and ASEAN regions. AltiusHub has enabled serialization and compliance operations across more than 50 regulated markets since its inception approximately two years ago.
Scale indicators3 records
Recent moves7 records
Expansion highlights5 records
Annora Pharma competitors and assessment
Company assessmentDirect peers
- Sandoz: Global generic pharmaceuticals division (formerly Novartis). Co-defendant with Annora in Mirum's Livmarli patent litigation, indicating direct overlap in US generic product development and ANDA filings for the same molecules.
- Cipla: Indian generic pharmaceutical major with global export operations across regulated and emerging markets. Co-bidder with Annora for Dapagliflozin supply to Chinese hospitals, indicating direct competition in the same generic molecules, channels, and regulated jurisdictions.
- Lupin Limited: Indian pharmaceutical company with major formulations manufacturing footprint including oral solids and injectables. Comparable as a USFDA-approved generic manufacturer serving US, India, and emerging markets with overlapping molecule portfolios.
- Sun Pharmaceutical Industries: Largest Indian specialty generics manufacturer with extensive US FDA-approved portfolio. Comparable in formulations manufacturing scale, US/EU regulatory approvals, and export reach to regulated markets.
- Hetero Labs: Sister company under Hetero Group, also engaged in pharmaceutical manufacturing. Closely comparable because it is a sibling entity of Annora with overlapping capabilities in active pharmaceutical ingredients and formulations, sharing customers, regulatory filings, and litigation matters (e.g., FIRDAPSE settlement).
- Natco Pharma: Indian generic pharmaceutical manufacturer with strong export focus in formulations. Co-bidder with Annora and Cipla for Chinese hospital generic drug supply, making it a direct peer in regulated and semi-regulated export markets.
- Zydus Lifesciences: Indian pharmaceutical major with global formulations and API operations. Co-defendant with Annora in Mirum's Livmarli patent litigation, indicating directly overlapping US generic product portfolios and competitive overlap in regulated markets.
- Dr. Reddy's Laboratories: Indian pharmaceutical major with substantial generics manufacturing for regulated markets. Comparable in scale of USFDA/EU-compliant formulations manufacturing and multi-dosage-form capability serving global export channels.
- Aurobindo Pharma: Large Indian generic pharmaceutical manufacturer with significant US and EU export presence. Comparable as a USFDA-compliant generic formulations manufacturer producing tablets, capsules, injectables, and other dosage forms for regulated markets.
Broad incumbents
- Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer with extensive US and global footprint. Comparable as a broad incumbent in generic formulations with multi-dosage capability, though much larger and more diversified across specialty, biosimilars, and consumer health.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Annora Pharma social profiles
Digital presenceAnnora Pharma compliance and trust
Trust signalCompliance3 records
Annora Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Annora Pharma leadership team
Management profileNumber of profiles
Annora Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Annora Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Annora Pharma
What does Annora Pharma do?
Annora Pharma manufactures generic pharmaceutical formulations including tablets, capsules, pellets, liquid orals, suppositories, and dry powder syrups at a 35-acre cGMP-compliant facility near Hyderabad, India. The company exports these generic medicines to regulated markets across the US, EU, GCC, LATAM, ASEAN, and China, with operations meeting Schedule M, USFDA, and European Regulatory Agency guidelines. It operates as the formulations subsidiary of Hetero Group and supports multi-jurisdictional serialization and regulatory compliance through an AI-based traceability platform.
Is Annora Pharma a public or private company?
Annora Pharma is a private company. It is classified as corporate owned and is currently operating.
When was Annora Pharma founded?
Annora Pharma was founded in 2016. It employs 501 to 1,000 people.
Where is Annora Pharma based?
Annora Pharma is headquartered in Sangareddi, India, in the Asia region.
How does Annora Pharma make money?
One revenue line is on record: generic Pharmaceutical Manufacturing and Export.
Who are Annora Pharma's main competitors?
Direct peers on record are Sandoz, Cipla, Lupin Limited, Sun Pharmaceutical Industries, Hetero Labs, Natco Pharma, Zydus Lifesciences, Dr. Reddy's Laboratories and Aurobindo Pharma. Teva Pharmaceutical Industries is listed as a broad incumbent.
Does Annora Pharma have an API?
No public API is recorded for Annora Pharma.
What industry is Annora Pharma in?
Annora Pharma's product category is Generic Pharmaceuticals Manufacturing. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAIABAD, Oral Solid Dose (OSD) Generics. Its NAICS code is 325412 and its SIC code is 2834.